Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 24,727 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $80.26, for a total transaction of $1,984,589.02. Following the sale, the chief operating officer owned 61,202 shares of the company’s stock, valued at approximately $4,912,072.52. The trade was a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $80.18 on Friday. The firm has a market capitalization of $6.55 billion, a price-to-earnings ratio of -21.79 and a beta of 2.20. The business’s 50 day simple moving average is $80.05 and its 200-day simple moving average is $70.43. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.88) earnings per share. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. lifted its stake in shares of Kymera Therapeutics by 21,538.1% during the 4th quarter. Rockefeller Capital Management L.P. now owns 25,533 shares of the company’s stock worth $1,987,000 after purchasing an additional 25,415 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the fourth quarter valued at $198,000. Virtu Financial LLC purchased a new position in Kymera Therapeutics during the fourth quarter worth about $2,123,000. T. Rowe Price Investment Management Inc. lifted its position in Kymera Therapeutics by 3.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock worth $49,001,000 after buying an additional 18,524 shares during the period. Finally, Invesco Ltd. boosted its stake in Kymera Therapeutics by 46.3% in the 4th quarter. Invesco Ltd. now owns 116,747 shares of the company’s stock worth $9,084,000 after buying an additional 36,940 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently issued reports on KYMR shares. Mizuho lifted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Wall Street Zen cut shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Citigroup raised their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Piper Sandler lifted their target price on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, HC Wainwright upped their price target on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.